Regeneron and Lilly's MAB are "spike targeting" MA
Post# of 148171
It will work well when given early in Covid infection for people with a variant that's similar to wild type / last year's.. people who are turned away from care until "they get worse" won't benefit as much. People who are infected with a variant with a mutated spike protein won't benefit as much. As time goes by, these Spike MABs will eventually, effectively, stop working.
Quote:
The US government is no longer distributing Eli Lilly's bamlanivimab into California, Arizona and Nevada because of the prevalence of a viral variant that is not susceptible to the monoclonal antibody, FDA acting commissioner Janet Woodcock told physicians taking part in a webinar with the American Medical Association ...Mar 17, 2021